Cargando…
Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
The majority of patients with human epidermal growth factor receptor 2 (Her2)‐positive gastric cancer develop refractory to Her2‐targeted therapy, where upregulation of immune checkpoints plays an essential role. Herein, a recombinant fully human IgG1 bispecific antibody IBI315 targeting both PD‐1 a...
Autores principales: | Lin, Wu, Zhang, Yingzi, Yang, Yan, Lin, Ben, Zhu, Mengjia, Xu, Jinling, Chen, YiRan, Wu, Weiwei, Chen, Bingliang, Chen, Xiangliu, Liu, Jin, Wang, Haohao, Teng, Fei, Yu, Xiongfei, Wang, Haiyong, Lu, Jun, Zhou, Quan, Teng, Lisong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602533/ https://www.ncbi.nlm.nih.gov/pubmed/37587833 http://dx.doi.org/10.1002/advs.202303908 |
Ejemplares similares
-
Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis (Adv. Sci. 30/2023)
por: Lin, Wu, et al.
Publicado: (2023) -
PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022) -
The Essential Factors of Establishing Patient-derived Tumor Model
por: Chen, Chuanzhi, et al.
Publicado: (2021) -
Gasdermin D in pyroptosis
por: Burdette, Brandon E., et al.
Publicado: (2021) -
Microbiota and metabolites alterations in proximal and distal gastric cancer patients
por: Yang, Yan, et al.
Publicado: (2022)